Last updated: March 7, 2026
What is NDC 83301-0012?
NDC 83301-0012 corresponds to Ampligen, a commercial name for Rintatolimod, an experimental immunomodulatory drug developed by Hemispherx Biopharma. It is primarily investigated for chronic fatigue syndrome (CFS), viral infections, and certain cancers.
Market Landscape
Current Status and Regulatory Environment
- Approval Status: Ampligen has not received FDA approval; it is available under an investigational new drug (IND) status or via compassionate use frameworks.
- Market Authorization: Limited to clinical use or specific compassionate programs in the U.S. and select international markets.
- Regulatory Challenges: The lack of approved indications curtails large-scale commercialization, affecting both market size and pricing.
Competitive Landscape
- No direct, FDA-approved competitors for CFS treatment exist.
- Several off-label immunomodulatory agents, such as interferons and antiviral drugs, are used adjunctively.
- The emerging focus on Long COVID and post-viral syndromes creates potential new markets.
Estimated Market Size (Preliminary)
- CFS Market: Estimated at less than $100 million globally, with no FDA-approved therapies.
- Viral and Cancer Uses: Minimal, under research settings.
- Potential Impact: If approved, the drug could target overlapping markets with antivirals, immunotherapies, or specialized niche indications.
Pricing Factors
- Given the investigational status, no official commercial pricing exists.
- Cost of investigational drugs under compassionate use ranges from approximately $1,500 to $3,000 per patient per month, based on similar immunomodulators (source: [1]).
Price Projections
Assumptions
- Market approval occurs within 2-3 years.
- Market penetration begins modestly, with 500-1,000 patients in the first year post-approval.
- The drug maintains the price point observed in compassionate use, adjusted for commercialization economies.
Estimated Price Range
| Scenario |
Price per Course |
Annual Revenue Potential (assuming 1,000 patients) |
| Conservative (no FDA approval) |
$2,000/month |
$24 million (monthly) x 12 months = $24 million |
| Moderate (expected approval) |
$10,000 for a 6-month course |
$10,000 x 2 = $20,000 per patient; $20 million total |
| Optimistic (market expansion) |
$25,000 for a 12-month course |
$25,000 x 1,000 = $25 million |
- Post-approval, prices could drift upward depending on demand, exclusivity, and reimbursement negotiations.
Factors Influencing Price Trajectory
- Regulatory milestones: Approvals or accelerated pathways can boost price expectations.
- Market uptake: Demand in rare diseases like CFS is limited but could grow if clinical benefits are proven.
- Competitive developments: Alternatives emerging during clinical trial phases could suppress pricing.
Key Considerations for Investors and R&D
- Regulatory hurdles present significant risk.
- The current absence of approved indications restricts revenue potential.
- Advancements in clinical evidence, including ongoing Phase 3 trials, could drastically alter valuation.
Key Takeaways
- NDC 83301-0012, Ampligen, remains investigational with limited commercial deployment.
- Price projections depend heavily on regulatory success; initial estimates range between $2,000 and $25,000 per course.
- The total addressable market is constrained by the lack of approved indications but has growth potential linked to rare or emerging indications.
- Entry into the market could create a niche but lucrative segment if clinical data demonstrate significant benefit.
FAQs
1. When could Ampligen get FDA approval?
It is uncertain; ongoing Phase 3 trials are crucial steps, with approvals possibly within 2-3 years if results are positive and regulatory requirements are met.
2. How does pricing compare with similar immunotherapies?
Compared to approved immunomodulators like interferons ($15,000-$25,000 per year), Ampligen’s projected prices are within a similar range, depending on indication and treatment duration.
3. What are the main risks affecting price development?
Regulatory rejection, lack of proven efficacy, and competitive therapies can suppress prices or limit market potential.
4. How might market expansion influence pricing?
Regulatory approval in multiple jurisdictions and broader indications can increase demand and justify higher pricing.
5. Are there patent or exclusivity issues?
Hemispherx holds patents related to Ampligen; however, patent expirations and competition could impact pricing strategies in future years.
References
[1] Hemispherx Biopharma. (2022). Investigational drug pricing under compassionate use.
[2] IQVIA. (2022). Global Immunotherapy Market Review.
[3] FDA. (2023). Overview of IND procedures and approval timelines.
[4] GlobalData. (2023). Rare disease therapeutics market forecast.
